



PATENT

Attorney Docket No. 39780-2630P1C21 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Ashkenazi et al.	Docket No.:	39780-2630P1C21
Serial No.:	09/978,423	Group Art Unit:	1648
Filing Date:	October 16, 2001	Examiner:	Le, Emily M.
For:	SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME		

Express Mail No.: EL 993 633 988 US
Mailing Date: April 11, 2005

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☒ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; **or**
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39780-2630P1C20).

Respectfully submitted,

HELLER EHRMAN WHITE & MCAULIFFE LLP

Dated: April 11, 2005

By: Leslie A. Mooi
Leslie A. Mooi, Reg. No. 37,047

275 Middlefield Road
Menlo Park, CA 94025-3506
(650) 324-7000
Customer No. 09157/35489



PATENT

Attorney Docket No. 39780-2630P1C21 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ashkenazi et al. Docket No.: 39780-2630P1C21
Serial No.: 09/978,423 Group Art Unit: 1648
Filing Date: October 16, 2001 Examiner: Le, Emily M.
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

Express Mail No.: EL 993 633 988 US

Mailing Date: April 11, 2005

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants note that U.S. Provisional Application No. 60/080328 states the following on page 27, lines 21- 25:

"A consensus DNA sequence was assembled relative to other EST sequence using phrap. This consensus sequence is herein designated DNA39848-from DNA (also termed "Consen1263" in Figure 3) (SEQ ID NO:3). The sequence "N85038" (SEQ ID NO:4) in Figure 3 was identified in a Merck/Wash U EST data collection, and "493521" (SEQ ID NO:5) in Figure 3 was identified in a data collection from Incyte Pharmaceuticals."


Applicants respectfully request that this information be considered by the Examiner.

- ☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☒ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; **or**
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith;
and
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39780-2630P1C20).


Respectfully submitted,

HELLER EHRMAN WHITE & MCAULIFFE LLP

Dated: April 11, 2005

By: 
Leslie A. Mooi, Reg. No. 37,047

275 Middlefield Road
Menlo Park, CA 94025-3506
(650) 324-7000
Customer No. 09157/35489

INFORMATION DISCLOSURE STATEMENT  PTO-1449		ATTY. DOCKET NO.		SERIAL NO.			
		39780-2630P1C21		09/978,423			
		APPLICANT <i>Ashkenazi et al.</i>					
		FILING DATE 10/16/2001		GROUP: 1648			
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	FILING DATE		
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Cai <i>et al.</i> , "Prior Exposure to Neurotrophins Block Inhibition of Axonal Regeneration by MAG and Myelin via a cAMP-Dependent Mechanism," <i>Neuron</i> , 22: 89-101, January 1999.						
	Sequence Alignment of Dayhoff, Accession No.: P_KIAA0951, Direct Submission, Submitted: February 4, 1999.						
	Dayhoff, Accession No. P_AAB33427, WO 200053758-A2, Pub Date: September 14, 2000, Avi Ashkenazi <i>et al.</i>						
	Dayhoff, Accession No. P_AAB44296, WO 200053756-A2, Pub Date: September 14, 2000, Avi Ashkenazi <i>et al.</i>						
	Dayhoff, Accession No. P_AAY41740, WO 199946281-A2, Pub Date: September 16, 1999, Wood <i>et al.</i>						
	Dayhoff, Accession No. B_AA86574, DNA Research Institute, Laboratory of DNA Technology, pp 1532-3, October 4, 1999, Ohara <i>et al.</i>						
	GenBank, Accession No.: P_AAC58592, WO 200053758-A2, Pub Date: September 14, 2000, Avi Ashkenazi <i>et al.</i>						
	GenBank, Accession No.: P_AB033086, DNA Research Institute, Laboratory of DNA Technology, pp 1532-3, October 4, 1999, Ohara <i>et al.</i>						
	Irie <i>et al.</i> , "Binding of N uroligins to PSD-95," <i>Science</i> , 277: 1511-1515, September 1997.						
	Sequence Alignment of SEQ ID NO:375 with Irie <i>et al.</i>						
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.